|Bid||5,150.0000 x 6100|
|Ask||5,295.0000 x 13000|
|Day's range||5,212.0000 - 5,288.9805|
|52-week range||3,680.0000 - 5,505.0000|
|PE ratio (TTM)||19.62|
|Earnings date||27 Jul 2017|
|Dividend & yield||2.80 (4.23%)|
|1y target est||67.04|
AstraZeneca is voluntarily recalling one lot of physician sample bottles of Brilinta — a blood-thinning drug prescribed to prevent stroke, heart attack and other heart problems — as a precautionary measure. The London-based pharmaceutical company, which has its U.S. headquarters in Wilmington, said the voluntary recall follows a report that a professional sample bottle containing eight, 90 milligram tablets of Brilinta also contained another medicine, Zurampic tablets, also manufactured by AstraZeneca (AZN).
There are lot of companies focusing on cancer drugs that pay dividends. AbbVie, AstraZeneca, and Pfizer stand at the top of the list.
The U.S. Food and Drug Administration has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016, and just nine at this stage last year. The European Medicines Agency has recommended 42 compared with a 2016 total of 81, and 31 in the first five months of last year. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.